Department of Pediatrics, Columbia University Medical Center, New York, NY, USA.
Nordic EMBL Partnership, Centre for Molecular Medicine Norway (NCMM), University of Oslo, Oslo, Norway; Institute of Automatic Control, Silesian University of Technology, Gliwice, Poland.
Trends Pharmacol Sci. 2019 Jun;40(6):403-418. doi: 10.1016/j.tips.2019.04.002. Epub 2019 May 7.
Metastasis is a major cause of cancer-related mortality, accounting for 90% of cancer deaths. The explosive growth of cancer biology research has revealed new mechanistic network information and pathways that promote metastasis. Consequently, a large number of antitumor agents have been developed and tested for their antimetastatic efficacy. Despite their exciting cytotoxic effects on tumor cells in vitro and antitumor activities in preclinical studies in vivo, only a few have shown potent antimetastatic activities in clinical trials. In this review, we provide a brief overview of current antimetastatic strategies that show clinical efficacy and review nanotechnology-based approaches that are currently being incorporated into these therapies to mitigate challenges associated with treating cancer metastasis.
转移是癌症相关死亡的主要原因，占癌症死亡人数的 90%。癌症生物学研究的飞速发展揭示了促进转移的新的机制网络信息和途径。因此，已经开发并测试了大量抗肿瘤药物来评估其抗转移疗效。尽管这些药物在体外对肿瘤细胞具有令人兴奋的细胞毒性作用，并且在体内临床前研究中具有抗肿瘤活性，但在临床试验中只有少数药物显示出有效的抗转移活性。在这篇综述中，我们简要概述了目前具有临床疗效的抗转移策略，并回顾了目前正在纳入这些治疗方法的基于纳米技术的方法，以减轻治疗癌症转移所面临的挑战。
